Cited by 117Atherosclerosis and Cardiovascular DiseasesPhagocytosis and Immune RegulationCholesterol and Lipid Metabolism

Interferon regulatory factor 5 controls necrotic core formation in atherosclerotic lesions by impairing efferocytosis

Open access
Seneviratne, Anusha N., Edsfeldt, Andreas, Cole, Jennifer E., Kassiteridi, Christina, Swart, Maarten, Park, Inhye, Green, Patricia, Khoyratty, Tariq +7 more·2017·Circulation

Abstract

Background: Myeloid cells are central to atherosclerotic lesion development and vulnerable plaque formation. Impaired ability of arterial phagocytes to uptake apoptotic cells (efferocytosis) promotes lesion growth and establishment of a necrotic core. The transcription factor interferon regulatory factor (IRF)-5 is an important modulator of myeloid function and programming. We sought to investigate whether IRF5 affects the formation and phenotype of atherosclerotic lesions. Methods: We investigated the role of IRF5 in atherosclerosis in 2 complementary models. First, atherosclerotic lesion development in hyperlipidemic apolipoprotein E-deficient (ApoE -/- ) mice and ApoE -/- mice with a genetic deletion of IRF5 (ApoE -/- Irf5 -/- ) was compared and then lesion development was assessed in a model of shear stress-modulated vulnerable plaque formation. Results: Both lesion and necrotic core size were significantly reduced in ApoE -/- Irf5 -/- mice compared with IRF5-competent ApoE -/- mice. Necrotic core size was also reduced in the model of shear stress-modulated vulnerable plaque formation. A significant loss of CD11c + macrophages was evident in ApoE -/- Irf5 -/- mice in the aorta, draining lymph nodes, and bone marrow cell cultures, indicating that IRF5 maintains CD11c + macrophages in atherosclerosis. Moreover, we revealed that the CD11c gene is a direct target of IRF5 in macrophages. In the absence of IRF5, CD11c - macrophages displayed a significant increase in expression of the efferocytosis-regulating integrin-β3 and its ligand milk fat globule-epidermal growth factor 8 protein and enhanced efferocytosis in vitro and in situ. Conclusions: IRF5 is detrimental in atherosclerosis by promoting the maintenance of proinflammatory CD11c + macrophages within lesions and controlling the expansion of the necrotic core by impairing efferocytosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.027844

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Impaired macrophage efferocytosis enhances atherogenesis and atherosclerotic plaque instability.

    “The impaired ability of macrophage efferocytosis would enhance atherogenesis [139,140,141] and atherosclerotic plaque instability [142,143,144].”
  • IRF5 transcription factor enhances vulnerable plaque formation in hyperlipidemic ApoE−/− mice by inducing pro-inflammatory CD11c+ macrophages within atherosclerotic lesions and increasing necrotic core expansion via inhibiting macrophage efferocytosis.

    “interferon regulatory factor 5 (IRF5) transcription factor enhances vulnerable plaque formation in hyperlipidemic apolipoprotein E-deficient (ApoE−/−) mice through the induction of pro-inflammatory CD11c+ macrophages within atherosclerotic lesions and increasing the expansion of the necrotic core by inhibiting macrophage efferocytosis [142].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Seneviratne, A. N., Edsfeldt, A., Cole, J. E., Kassiteridi, C., Swart, M., Park, I., Green, P., Khoyratty, T., Saliba, D., Goddard, M. E., Sansom, S. N., Goncalves, I., Krams, R., Udalova, I. A., & Monaco, C.
Affiliations
  • Queen Mary University of London (GB)
  • From Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, United Kingdom (A.N.S., A.E., J.E.C., C.K., M.S., I.P., P.G., T.K., D.S., M.E.G., S.N.S., I.A.U., C.M.); Department of Bioengineering, Imperial College London, United Kingdom (A.N.S., R.K.); Experimental Cardiovascular Research Unit, Clinical Research Centre, Clinical Sciences Malmö, Lund University, Sweden (A.E., I.G.); Department of Cardiology, Skåne...
Corresponding author
Monaco, Claudia
Venue
Circulation
Published
2017-09-19
Volume
136
Issue
12
Pages
1140-1154
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2735394628
Cited by
117
References
40
Citations by year
2026: 11 · 2025: 21 · 2024: 12 · 2023: 8 · 2022: 15 · 2021: 16 · 2020: 14 · 2019: 10 · 2018: 9 · 2017: 1
FWCI
4.21
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Circulation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion, cc-by)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • Kennedy Trust for Rheumatology Research (KENN161701)
  • British Heart Foundation (PG/15/49/31595, RG/11/13/29055)
  • Novo Nordisk Fonden (NNF15SA0018346, NNF15SA0018486)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
IRF5, atherosclerosis, necrotic core, efferocytosis, CD11c+ macrophages, CD61, MFG-E8, vulnerable plaque, shear stress, ApoE-deficient mice, transcriptional regulation
MeSH terms
Animals, Aorta, Apolipoproteins E, Bone Marrow Cells, Cells, Cultured, Immunohistochemistry, Lymph Nodes, Macrophages, Mice, Inbred C57BL, Necrosis, Phagocytosis, Mice, Knockout, Shear Strength, CD11c Antigen, Integrin beta3, Atherosclerosis, Interferon Regulatory Factors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review